Changes in vitreous @entity7 , @entity540 and XXXX in @entity6 after intravitreal bevacizumab.

@entity1 @entity82 @entity6 @entity7 @entity12938 @entity540
AIM: To evaluate the relationship between intravitreal bevacizumab (IVB) treatment and the levels of vitreous @entity7 ( @entity7 ), @entity540 ( @entity540 ) and vitreous-retina surface @entity82 in @entity1 with @entity6 ( @entity6 ). METHODS: This study was a prospective, open-label, controlled, randomized clinical trial. Sixty-eight eyes of @entity6 @entity1 (n=53) and macular hole @entity1 (n=15) were enrolled in this study. Thirty-four eyes of the @entity6 @entity1 received IVB before vitrectomy. Twenty-three of the 34 @entity6 @entity1 received IVB treatment 5d before vitrectomy (subgroup a), and 11 of the 34 @entity6 @entity1 received IVB treatment greater than 2wk prior to vitrectomy (subgroup b). Nineteen of the @entity6 @entity1 did not receive IVB treatment at any time prior to vitrectomy. The levels of @entity540 and @entity7 in vitreous samples were measured using enzyme-linked immunosorbent assay (ELISA) and the degree of @entity82 was characterized using clinical data and data obtained intra-operatively. RESULTS: In @entity6 @entity1 , @entity7 and @entity540 levels were significantly increased compared to non- @entity6 (control) subject' @entity12938 (P<0.01). In @entity6 @entity1 , vitreous @entity7 levels were significantly decreased following IVB treatment compared to @entity6 @entity1 that did not receive IVB treatment (P<0.01). The degree of @entity82 was significantly increased in subgroup b compared to subgroup a(P<0.05) and to @entity1 that did not receive IVB (P<0.05). Vitreous @entity540 levels were significantly greater in subgroup b than subgroup a (P<0.01) or in @entity1 who did not receive IVB treatment (P<0.05). A Spearman's rank correlation test indicated that higher levels of vitreous @entity540 , but not @entity7 , correlated with the degree of @entity82 . CONCLUSION: We found that @entity540 levels increase in @entity6 @entity1 's vitreous after IVB treatment longer than two weeks prior to vitrectomy and correlated with the degree of @entity82 after IVB treatment. These findings suggest vitreous @entity82 is increased in @entity6 @entity1 after IVB treatment may be due to increased levels of @entity540 .
